Big pharma, Partnering, Pharma

AstraZeneca pharma alliances with ADDC

Posted on 23 December 2014

Tags: , , ,

ADDC provided the opportunity to its members to access AstraZeneca's high quality compound library through a competitive Request for Proposals process.

Each of the five selected institutions will have access to up to 250,000 compounds from AstraZeneca's internal screening library.

Selected institutions will be working closely with AstraZeneca scientists in oncology, diabetes and psychiatric disease areas.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

AstraZeneca and the selected institutions will be negotiating an option agreement prior to pursuing screening and drug development work.

For further deal information visit Current Agreements (subscription required)


Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Report:   Top 50 Big Pharma Partnering and M&A Deal Trends

Report:   Top 50 Big Biotech Partnering and M&A Deal Trends


Print Friendly, PDF & Email

Leave a Reply